Anteris Technologies Global (NASDAQ:AVR) Sees Large Volume Increase – Time to Buy?

Anteris Technologies Global Corp. (NASDAQ:AVR) shares saw strong trading volume on Monday. 1,462,601 shares were traded during mid-day trading, an increase of 27% from the average daily volume of 1,147,313 shares. The stock last traded at $5.7950 and had previously closed at $6.31.

Analysts Set New Price Targets

Several research firms have recently issued reports on AVR. Barclays upgraded Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price target on shares of Anteris Technologies Global in a research note on Wednesday, October 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $14.00.

Anteris Technologies Global Stock Performance

The stock’s fifty day moving average is $7.56 and its two-hundred day moving average is $7.37. The firm has a market cap of $574.04 million, a price-to-earnings ratio of -3.02 and a beta of 2.02.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%. The business had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. During the same period last year, the company earned ($0.58) earnings per share. Sell-side analysts predict that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current year.

Insider Transactions at Anteris Technologies Global

In other news, major shareholder L1 Capital Pty Ltd acquired 648,455 shares of the business’s stock in a transaction dated Monday, October 5th. The stock was acquired at an average price of $7.51 per share, for a total transaction of $4,869,897.05. Following the completion of the acquisition, the insider directly owned 12,778,380 shares in the company, valued at $95,965,633.80. This represents a 5.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders acquired 1,554,730 shares of company stock worth $11,694,513 and sold 1,305,369 shares worth $11,380,022. Insiders own 4.50% of the company’s stock.

Institutional Trading of Anteris Technologies Global

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Anteris Technologies Global during the second quarter worth $56,846,000. Nantahala Capital Management LLC purchased a new stake in shares of Anteris Technologies Global during the 2nd quarter worth about $33,325,850. ADAR1 Capital Management LLC bought a new position in Anteris Technologies Global during the second quarter valued at approximately $30,979,000. Perceptive Advisors LLC lifted its stake in shares of Anteris Technologies Global by 104.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock valued at $19,011,000 after purchasing an additional 1,750,000 shares during the last quarter. Finally, Militia Capital Management LLC acquired a new position in shares of Anteris Technologies Global during the 1st quarter valued at about $3,663,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a medical device company focused on developing structural heart products for the treatment of heart valve disease. Its primary focus is transcatheter aortic valve replacement (TAVR), a minimally invasive procedure used to replace a diseased aortic valve without traditional open-heart surgery.

The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the function and hemodynamic performance of a healthy human aortic valve.